Silver sulfadiazine is an antibacterial medication that is
used to treat second and third-degree burns on the skin. Silver sulfadiazine is
classified as an essential medicine by the World Health Organization and is
used to treat skin burns. Silver sulfadiazine is used to treat urinary tract
infections by inhibiting the growth of yeast and bacteria (UTI). When it's
coupled with pyrimethamine, it's used to treat toxoplasmosis. Furthermore, a
common anti-burn cream contains 1% silver sulfadiazine, which is important to
keep in mind because too much of it is hazardous. Some organisations, however,
do not encourage its use because it has been the subject of inquiry and
speculation. Furthermore, silver sulfadiazine has caused various side effects
such as lack of appetite, dizziness, and nausea.
Market Outlook
During the forecast period, the global
silver sulfadiazine market is expected to grow significantly
(2019-2027). Burn injuries are regarded critical medical issues, far more so
than previous outbreaks like polio. According to the World Health Organization,
over 180,000 people die from burns each year, with the majority of these deaths
occurring in developing countries. Burn injuries that do not result in death
are also the major cause of morbidity. This is likely to boost demand for
anti-burn creams and lotions, propelling the market forward. Furthermore,
silver sulfadiazine has been widely utilised in hospitals across North America
since it is regarded as a highly effective burn treatment.
However, minor side effects such as nausea, lack of
appetite, and dizziness are associated with silver sulfadiazine, which may
limit demand for the product and, as a result, the worldwide silver
sulfadiazine market's growth. Furthermore, rising silver prices, which are one
of the primary raw materials used in the production of silver sulfadiazine, are
predicted to stymie output.
Market Regional
During the projected period, North America is expected to
hold the highest market share in the worldwide silver sulfadiazine market. This
is due to an increase in the number of burn cases and the need for wound-care
products. According to the National Fire Protection Association (NFPA), a
civilian dies in a fire every two hours, resulting in an increase in the need
for wound-care goods.
Furthermore, the industry has been driven by increased
government initiatives to fund research and development of drugs to treat burn
wounds. Furthermore, due to rising demand for silver sulfadiazine from growing
economies such as India and China, the Asia Pacific market is likely to grow
significantly. Australia, China, and India are anticipated to become new
revenue providers in the region.
Market Players
3M Company, Baxter International, Inc., Monarch
Pharmaceuticals, Teva Pharmaceutical Industries Ltd, and Johnson & Johnson
Limited are some of the major participants in the worldwide silver sulfadiazine
market.
Comments
Post a Comment